Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
02:43:17 EDT Tue 21 May 2024
Enter Symbol
or Name
USA
CA



News for U:MBRX from 2023-05-22 to 2024-05-21 - 40 items News ReleasesIn The NewsOther CAUS
DateSymPriceTypeHeadline
2024-05-16 08:32U:MBRXNews ReleaseMoleculin Abstract Accepted for Poster Presentation at the European Hematology Association (EHA) 2024 Hybrid Congress
2024-05-15 08:38U:MBRXNews ReleaseMoleculin Announces Commencement of NIH-Funded Phase 2 Clinical Trial of STAT3 Inhibitor for the Treatment of Glioblastoma (NU 21C06)
2024-05-13 07:30U:MBRXNews ReleaseMoleculin Reports First Quarter 2024 Financial Results and Provides Corporate Update
2024-05-09 08:30U:MBRXNews ReleaseMoleculin Announces U.S. Patent Issue Notification for Lipid-Based Delivery Technology for Annamycin
2024-05-08 08:45U:MBRXNews ReleaseMoleculin to Report First Quarter 2024 Financial Results on May 10, 2024 and Host Conference Call and Webcast
2024-05-07 08:55U:MBRXNews ReleaseMoleculin Reports Higher AML Complete Remission (CR) Rates and Significant Durability with Additional Interim Subject Data
2024-05-02 09:00U:MBRXNews ReleaseMoleculin to Host Virtual AML Clinical Day Featuring Internationally Renowned Clinician, Martin S. Tallman, MD, on May 7, 2024
2024-05-01 08:50U:MBRXNews ReleaseMoleculin Announces Formation of Scientific Advisory Board to Support Development of Annamycin
2024-04-25 09:48U:MBRXNews ReleaseMoleculin Biotech (NASDAQ:MBRX) Participates in Virtual Investor "What This Means" Segment Hosted by JTC Team
2024-04-18 08:30U:MBRXNews ReleaseEuropean Medicines Agency (EMA) Grants Orphan Drug Designation for Moleculin's Treatment of Acute Myeloid Leukemia (AML)
2024-04-10 08:30U:MBRXNews ReleaseMoleculin Announces Presentation of Positive Data Demonstrating High Anti-Cancer Activity of Annamycin and Non-Cardiotoxic Properties
2024-03-28 10:45U:MBRXNews ReleaseMoleculin to Present at the MedInvest Biotech & Pharma Investor Conference
2024-03-27 09:25U:MBRXNews ReleaseMoleculin to Participate in the Virtual Investor Lunch Break: The Moleculin Opportunity
2024-03-27 09:05U:MBRXNews ReleaseMoleculin Announces U.S. Patent Issue Notification for Annamycin Targeting Unmet Need in AML
2024-03-25 07:30U:MBRXNews ReleaseMoleculin Announces Positive Interim Data in Annamycin MB-106 Phase 1B/2 AML Trial
2024-03-22 16:05U:MBRXNews ReleaseMoleculin Reports Full Year 2023 Financial Results
2024-03-20 07:30U:MBRXNews ReleaseMoleculin to Report Full Year 2023 Financial Results on March 22, 2024 and Host Conference Call and Webcast
2024-03-19 16:30U:MBRXNews ReleaseMoleculin Announces Reverse Stock Split
2024-03-12 09:05U:MBRXNews ReleaseMoleculin to Present at the 36th Annual ROTH Conference
2024-01-24 08:50U:MBRXNews ReleaseMoleculin Announces 2023 Year-End Annamycin Clinical Trials Preliminary Data and 2024 Expectations for Multiple Data Readouts and Transition to Pivotal Phase 2B/3
2023-12-20 21:16U:MBRXNews ReleaseMoleculin Announces Pricing of $4.5 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market
2023-12-11 08:50U:MBRXNews ReleaseMoleculin Presents Positive Interim Data from Phase 1B/2 Clinical Trial in AML at Meeting with KOL's in Conjunction with ASH Annual Meeting
2023-11-13 08:05U:MBRXNews ReleaseMoleculin Announces Positive Interim Data in Annamycin Clinical Trials: MB-106 AML Trial Complete Response (CR) Rate of 38% and MB-107 STS Lung Mets Trial Median Phase 1B Extended Overall Survival of 11 Months
2023-11-13 08:00U:MBRXNews ReleaseMoleculin Reports Third Quarter 2023 Financial Results
2023-11-07 08:45U:MBRXNews ReleaseMoleculin to Report Third Quarter Financial Results on November 13, 2023 and Host Conference Call and Webcast
2023-11-06 08:35U:MBRXNews ReleaseMoleculin Presents Positive Preliminary Efficacy Findings from Phase 1B/2 Clinical Trial Demonstrating 64% Stable Disease Rate Through Two Cycles of Annamycin for the Treatment of Soft Tissue Sarcomas (STS) Lung Metastases
2023-10-11 09:05U:MBRXNews ReleaseMoleculin to Participate in the Virtual Investor Ask the CEO Conference
2023-10-02 08:40U:MBRXNews ReleaseMoleculin Doses First Subjects in Phase 2 Portion of Clinical Trial Evaluating Annamycin in Combination with Cytarabine (Ara-C) for the Treatment of Acute Myeloid Leukemia (AML)
2023-09-21 08:50U:MBRXNews ReleaseMoleculin Announces Completion of Enrollment in U.S. Phase 1B/2 Clinical Trial Evaluating Annamycin for the Treatment of Soft Tissue Sarcoma Lung Metastases (MB107)
2023-09-18 08:40U:MBRXNews ReleaseMoleculin Announces New Positive Independent Report of No Cardiotoxicity in Annamycin
2023-09-14 08:35U:MBRXNews ReleaseMoleculin Announces Abstract Accepted for Poster Presentation at the 2023 Connective Tissue Oncology Society (CTOS) Annual Meeting
2023-09-05 08:35U:MBRXNews ReleaseMoleculin to Present at the H.C. Wainwright 25th Annual Global Investment Conference
2023-08-11 06:45U:MBRXNews ReleaseMoleculin Reports Second Quarter 2023 Financial Results
2023-08-10 16:05U:MBRXNews ReleaseMoleculin Provides Update on Ongoing Clinical Trials and Outlines Expected Upcoming Milestones
2023-08-07 08:40U:MBRXNews ReleaseMoleculin Retains Shareholder Intelligence Services, LLC to Investigate Potential Naked Short Selling
2023-08-03 08:45U:MBRXNews ReleaseMoleculin to Report Second Quarter Financial Results on August 11, 2023 and Host Conference Call and Webcast
2023-07-13 08:40U:MBRXNews ReleaseMoleculin Announces Publication of Data from Successful European Phase 1 Trial Evaluating Annamycin as Single Agent Treatment of Relapsed or Refractory Acute Myeloid Leukemia (AML)
2023-07-06 08:45U:MBRXNews ReleaseMoleculin to Participate in the Virtual Investor Summer Spotlight Series
2023-06-13 08:35U:MBRXNews ReleaseMoleculin to Participate in the Healthcare Virtual Conference Presented by Maxim Group LLC and Hosted by M-Vest
2023-05-30 09:05U:MBRXNews ReleaseMoleculin Announces Adjournment of 2023 Annual Meeting to June 15, 2023